<DOC>
	<DOCNO>NCT02568267</DOCNO>
	<brief_summary>This open-label , multicenter , global Phase 2 basket study entrectinib ( RXDX-101 ) treatment patient solid tumor harbor NTRK1/2/3 , ROS1 , ALK gene fusion . Patients assign different basket accord tumor type gene fusion .</brief_summary>
	<brief_title>Basket Study Entrectinib ( RXDX-101 ) Treatment Patients With Solid Tumors Harboring NTRK 1/2/3 ( Trk A/B/C ) , ROS1 , ALK Gene Rearrangements ( Fusions )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis locally advance metastatic solid tumor harbor NTRK1/2/3 , ROS1 , ALK gene rearrangement Note : Patients diagnose anaplastic large cell lymphoma ( ALCL ) harbor gene rearrangement interest may eligible provided meet inclusion/exclusion criterion For patient enrol via local molecular testing , archival fresh tumor tissue ( unless medically contraindicate ) require submit independent central molecular test Ignyta 's CLIA laboratory postenrollment Measurable evaluable disease Patients CNS involvement , include leptomeningeal carcinomatosis , either asymptomatic previouslytreated control , allow Prior anticancer therapy allow ( exclude approve investigational Trk , ROS1 , ALK inhibitors patient tumor harbor respective gene rearrangement ) Note : prior treatment crizotinib permit ALK ROS1rearranged NSCLC patient present CNSonly progression . Other ALK inhibitor prohibit . At least 2 week 5 halflives , whichever short , must elapse prior chemotherapy small molecule target therapy At least 4 week must elapse since completion antibodydirected therapy Prior radiotherapy allow 14 day elapse since end treatment Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 minimum life expectancy 4 week Adequate organ function define per protocol Ability swallow entrectinib intact Other protocol specify criterion Current participation another therapeutic clinical trial Prior treatment approve investigational Trk , ROS1 , ALK inhibitors patient tumor harbor respective gene rearrangement Note : prior treatment crizotinib permit ALK ROS1rearranged NSCLC patient present CNSonly progression . Other ALK inhibitor prohibit . History previous cancer would interfere determination safety efficacy Incomplete recovery surgery History nonpharmacologically induce prolonged QTc interval History additional risk factor torsade de pointes Peripheral neuropathy Grade ≥ 2 Known active infection Active gastrointestinal disease malabsorption syndromes Known interstitial lung disease , interstitial fibrosis , history tyrosine kinase inhibitorinduced pneumonitis Other protocol specify criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Entrectinib</keyword>
	<keyword>RXDX-101</keyword>
	<keyword>TrkA</keyword>
	<keyword>TrkB</keyword>
	<keyword>TrkC</keyword>
	<keyword>NTRK1</keyword>
	<keyword>NTRK2</keyword>
	<keyword>NTRK3</keyword>
	<keyword>ROS1</keyword>
	<keyword>ALK</keyword>
	<keyword>Trk Fusions</keyword>
	<keyword>NTRK Gene Rearrangements</keyword>
	<keyword>ROS1 Fusions</keyword>
	<keyword>ROS1 Gene Rearrangements</keyword>
	<keyword>ALK Fusions</keyword>
	<keyword>ALK Gene Rearrangements</keyword>
	<keyword>Basket study</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Salivary gland cancer</keyword>
	<keyword>Primary brain tumor</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Sarcomas</keyword>
	<keyword>Papillary thyroid cancer</keyword>
	<keyword>Renal cell cancer</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Head &amp; Neck cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
</DOC>